logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
S

Spencer C. Behr

University of California System
H指数:32
被引数:4,867

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Phase II trial with nivolumab and sorafenib in HCC identified enrichment of immunosuppressive monocytes in patients with Child-Pugh B liver dysfunction

II期临床试验中使用nivolumab和sorafenib治疗HCC，发现Child-Pugh B肝功能不全患者中免疫抑制性单核细胞富集。

JHEP Reports
IF7.5
2026-03-120
OAAI
Bridget P. Keenan; Zenghua Fan; Bryan Khuong Le; Quincy Harris; Jocelin Chen; Matthew Clark; Averey Lea; Li Zhang; Alexander Cheung; Frances Lara; John D. Gordan; Paige Bracci; Spencer C. Behr; Lawrence Fong; Alan P. Venook; Edward J. Kim; Robin K. Kelley
Cabozantinib for advanced grade 3 neuroendocrine tumors: subgroup analysis of the phase 3 CABINET trial (Alliance A021602)

卡博赞替尼用于高级别3级神经内分泌肿瘤：CABINET（Alliance A021602）三期试验的亚组分析

Endocrine-Related Cancer
IF4.6
2026-01-010
PRE
Strosberg, Jonathan R.; Zemla, Tyler; Geyer, Susan; Pulsipher, Sydney; Ou, Fang-Shu; Behr, Spencer; Raj, Nitya; Vijayvergia, Namrata; Dasari, Arvind; O'Reilly, Eileen M.; Meyerhardt, Jeffrey A.; Wolin, Edward M.; Halfdanarson, Thorvardur R.; Chan, Jennifer A.
Cabozantinib versus placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET Trial/Alliance A021602): Updated results including progression free-survival (PFS) by blinded independent central review (BICR) and subgroup analyses

卡博赞替尼 versus 安慰剂用于既往治疗后进展的晚期神经内分泌肿瘤（NET）（CABINET 试验/Alliance A021602）：更新结果包括根据盲态独立中心审查（BICR）的无进展生存期（PFS）及亚组分析

ANNALS OF ONCOLOGY
IF65.4
2024-09-010
PRE
Chan, J.; Geyer, S.; Zemla, T.; Knopp, M. V.; Behr, S. C.; Pulsipher, S.; Acoba, J.; Shergill, A.; Wolin, E. M.; Halfdanarson, T. R.; Konda, B.; Trikalinos, N.; Shaheen, S.; Vijayvergia, N.; Dasari, N. A.; Strosberg, J.; Kohn, E. C.; Kulke, M.; O'Reilly, E. M.; Meyerhardt, J.
Alliance A021602: Phase III, double-blinded study of cabozantinib versus placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET)

联盟A021602: 卡博替尼与安慰剂治疗晚期神经内分泌肿瘤 (NET) 的III期双盲研究 (内阁)

ANNALS OF ONCOLOGY
IF65.4
2023-10-0118
PRE
Chan, J.; Geyer, S.; Ou, F. S.; Knopp, M.; Behr, S.; Zemla, T.; Acoba, J.; Shergill, A.; Wolin, E. M.; Halfdanarson, T. R.; Trikalinos, N.; Konda, B.; Vijayvergia, N.; Dasari, N. A.; Strosberg, J.; Kohn, E. C.; Kulke, M. H.; O'Reilly, E. M.; Meyerhardt, J. A.

研究方向

暂未获取到该数据
R
Robert R. Flavell
H 指数:34论文数:469被引数:4,416
T
Thomas A. Hope
H 指数:64论文数:424被引数:1.6万
Y
Youngho Seo
H 指数:46论文数:734被引数:8,262
M
Michael J. Evans
H 指数:57论文数:335被引数:1.2万
R
Rahul Aggarwal
H 指数:48论文数:937被引数:1.0万
P
Peter R. Carroll
H 指数:149论文数:1,425被引数:10.6万
C
Courtney Lawhn-Heath
H 指数:18论文数:53被引数:1,342
M
Miguel Hernandez Pampaloni
H 指数:24论文数:137被引数:3,331
E
Eric J. Small
H 指数:118论文数:1,322被引数:6.8万
H
Henry F. VanBrocklin
H 指数:43论文数:563被引数:5,338